Chemical Property of 1-[[4-(1,4,8,11-Tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;hydrochloride
Chemical Property:
- Boiling Point:657.5 °C at 760 mmHg
- Flash Point:361.8 °C
- PSA：78.66000
- Density:0.962g/cm3
- LogP:8.68040
- Storage Temp.:−20°C
- Solubility.:H2O: ≥10 mg/mL, clear
- Hydrogen Bond Donor Count:7
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:4
- Exact Mass:538.4238215
- Heavy Atom Count:37
- Complexity:456
- Purity/Quality:
-
≥98% *data from raw suppliers
AMD 3100 octahydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Safety Statements:
22-24/25
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl
-
Description
Plerixafor (155148-31-5) is a highly selective CXCR4 antagonist (IC50 = 20-130 nM).1,2 Originally investigated as an HIV replication inhibitor.3 Plerixafor has been investigated for the treatment autoimmune diseases and various cancers.4 Clinically useful for the mobilization of hematopoietic stem cells in the treatment of blood cancers.
-
Uses
Plerixafor Hydrochloride (1:8), is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients. It is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). Plerixafor 8HCl (AMD3100 8HCl) is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively - See more at: http://www.selleckchem.com/products/plerixafor-8hcl-db06 A specific CXCR4 antagonist.
-
Clinical Use
Plerixafor hydrochloride, a chemokine CXCR4 (SDF-1) antagonist,
was launched by Genzyme for the treatment of enhancing
mobilization of hematopoietic stem cells for autologous transplantation
in patients with lymphoma and enhancing mobilization of
hematopoietic stem cells for transplantation in patients with multiple
myeloma. Being a CXCR4 antagonist, a specific cellular chemokine
receptor, plerixafor triggers the rapid movement of stem
cells out of the bone marrow and into circulating blood where
the stem cells can be collected for use in stem cell transplants.
Regarding its use for cardiac applications, some clinical data suggests
that the presence of stem cells circulating in the bloodstream
or directly injected into the hearts of patients who have suffered a
heart attack may result in improved cardiac function.
